公开(公告)号：US20240053326A1

公开(公告)日：2024-02-15

申请号：US18230872

申请日：2023-08-07

Applicant: BROWN UNIVERSITY

Inventor： Wafik S. El-Deiry ,  Kelsey E. Huntington ,  Anna Louie

IPC: G01N33/50

CPC classification number: G01N33/5041 ,  G01N2800/52 ,  G01N2333/475 ,  G01N2333/521

Abstract: A method of treating a subject having colon cancer with a small molecule drug for treating colon cancer is described. The method includes determining the effect of the small molecule drug on the release of a plurality of immunomodulating factors by colon cancer cells; and treating the subject with a therapeutically effect amount of the drug if the effect of the drug on the release of immunomodulating factors indicates that the drug promotes anti-tumor immunity, or selecting a different drug for treating colon cancer if the effect of the drug on immunomodulating factor release indicates that the drug does not promote anti-tumor immunity. Methods of evaluating ongoing treatment using the method are also described.

公开(公告)号：US20230404982A1

公开(公告)日：2023-12-21

申请号：US18151028

申请日：2023-01-06

Applicant: The Board of Trustees of the Leland Stanford Junior University

Inventor： Edda SPIEKERKOETTER ,  Marlene RABINOVITCH ,  Philip A. BEACHY ,  David SOLOW-CORDERO

IPC: A61K31/436 ,  G01N33/50

CPC classification number: A61K31/436 ,  G01N33/5041 ,  G01N2333/912

Abstract: A method for reducing pulmonary hypertension in a mammal that employs FK506 is provided. In certain embodiments, the method comprises administering FK506 to a mammal having pulmonary arterial hypertension associated with defective MBPR2 signaling at a dosage sufficient to reduce blood pressure in the pulmonary artery of the mammal.

公开(公告)号：US11793180B2

公开(公告)日：2023-10-24

申请号：US16327218

申请日：2017-08-21

Applicant: CHUGAI SEIYAKU KABUSHIKI KAISHA

Inventor： Koichi Jishage ,  Hiroshi Hino ,  Takahiro Ishiguro ,  Yasuko Kinoshita

IPC: A01K67/027 ,  C12N15/85 ,  G01N33/50 ,  C07K16/28 ,  C07K16/30 ,  C12N5/10 ,  C07K14/705 ,  A61K39/00

CPC classification number: A01K67/0278 ,  C07K14/705 ,  C07K16/2809 ,  C07K16/303 ,  C12N5/10 ,  C12N15/85 ,  G01N33/5041 ,  G01N33/5088 ,  A01K2217/052 ,  A01K2217/072 ,  A01K2217/206 ,  A01K2227/105 ,  A61K2039/505 ,  C07K2317/31 ,  C12N2015/8518

Abstract: Genetically modified non-human animals which are deficient in expression of an endogenous GPC3 polypeptide and express a human GPC3 polypeptide at a physiologically adequate level; methods for producing the non-human animals; and methods for evaluating test substances using the non-human animals. Furthermore, methods for evaluating test substances regarding their safety, therapeutic effects on diseases, pharmacokinetics, in vivo distribution, and such, using the non-human animals as models.

公开(公告)号：US20230184746A1

公开(公告)日：2023-06-15

申请号：US17793615

申请日：2021-01-21

Applicant: Firmenich Incorporated

Inventor： Guy Servant ,  Mark Williams ,  Nicole Servant

IPC: G01N33/50

CPC classification number: G01N33/5041 ,  G01N2333/726

Abstract: The present disclosure relates generally to methods and materials for the identification of compounds that modulate (e.g., enhance, agonize, or antagonize) G protein-coupled receptor (GPCRs), such as those involved in taste. Examples of such GPCR include the TAS1R proteins and the TAS2R proteins that are involved in sensing sweet taste. In certain aspects, the disclosure provides cell-based and label-free assays that use highly sensitive biosensors to detect candidate taste modulator compounds by their alteration of GPCR activity. In some embodiments, such cell-based and label-free assays may be used to detect changes in cell mass distribution, cell adhesion, or cell morphology, resulting from contact with a candidate taste modulator compound. In some embodiments, such assays detect GPCR activation with greatly improved sensitivity compared to conventional assay methods.

公开(公告)号：US20190219581A1

公开(公告)日：2019-07-18

申请号：US16252424

申请日：2019-01-18

Applicant: Ventana Medical Systems, Inc. ,  Cell Signaling Technology, Inc.

Inventor： Sarah S. Bacus ,  Bradley L. Smith

IPC: G01N33/574 ,  G01N33/50 ,  C07K16/28 ,  C07K16/40 ,  G01N33/68

CPC classification number: G01N33/57415 ,  C07K16/2863 ,  C07K16/40 ,  C07K2317/24 ,  G01N33/5041 ,  G01N33/574 ,  G01N33/6893 ,  G01N2333/4703 ,  G01N2333/4756 ,  G01N2333/71 ,  G01N2333/912 ,  G01N2333/9121 ,  G01N2440/14 ,  G01N2800/52

Abstract: This invention provides methods for determining or predicting response to HER2-directed therapy in an individual.

公开(公告)号：US20190203177A1

公开(公告)日：2019-07-04

申请号：US16311852

申请日：2017-06-23

Applicant: The Brigham and Women`s Hospital, Inc.

Inventor： Olivier Pourquie ,  Jerome Chal

IPC: C12N5/077 ,  A61K35/35 ,  G01N33/50 ,  A61K49/00

CPC classification number: C12N5/0653 ,  A61K35/35 ,  A61K49/0008 ,  A61P5/00 ,  C12N2500/25 ,  C12N2501/105 ,  C12N2501/115 ,  C12N2501/12 ,  C12N2501/155 ,  C12N2501/385 ,  C12N2501/39 ,  C12N2501/395 ,  C12N2501/415 ,  C12N2506/02 ,  C12N2506/45 ,  C12N2533/54 ,  C12Q1/6881 ,  C12Q2600/158 ,  G01N33/5023 ,  G01N33/5041 ,  G01N33/5044 ,  G01N2800/044

Abstract: A population of Brown adipose tissue (BAT) cells generated from embryonic stem cells (ES) or induced pluripotent stem cells (iPS), called iBAT, the use thereof, methods to obtain iBAT by directed differentiation of ES/iPS, and media compositions to obtain iBAT.

公开(公告)号：US20180318189A1

公开(公告)日：2018-11-08

申请号：US15770950

申请日：2015-10-28

Applicant: Symrise AG

Inventor： Hanns Hatt ,  Günter Gisselmann ,  Ivonne Wallrabenstein ,  Marco Singer ,  Johannes Panten

IPC: A61K8/34 ,  A61Q13/00 ,  G01N33/50 ,  G01N33/566

CPC classification number: A61K8/342 ,  A61Q13/00 ,  C11B9/0019 ,  G01N33/5041 ,  G01N33/566 ,  G01N2500/04

Abstract: Norlimbanol in general and particularly its isomer mixture Timberol®, an amber-woody fragrance, is able to specifically inhibit the trimethylamine-induced h TAAR5 activation up to 96%. Moreover, human psychophysical data showed that the presence of Timberol® increases the olfactory detection threshold for the characteristic fishy odor of trimethylamine by almost one order of magnitude.

公开(公告)号：US10073082B2

公开(公告)日：2018-09-11

申请号：US15028846

申请日：2014-10-03

Applicant: UNIVERSITY HEALTH NETWORK ,  BECKMAN COULTER, INC.

Inventor： T. Vincent Shankey ,  Sergei Gulnik ,  Lidice L. Lopez ,  David W. Hedley ,  Sue Chow

IPC: G01N33/49 ,  G01N33/53 ,  G01N33/50 ,  C12Q1/37 ,  G01N33/58 ,  G01N15/14 ,  C07K14/47 ,  C07K16/18 ,  G01N15/00 ,  G01N15/10

CPC classification number: G01N33/5041 ,  C07K14/47 ,  C07K16/18 ,  C12Q1/37 ,  G01N15/14 ,  G01N33/4915 ,  G01N33/5011 ,  G01N33/5047 ,  G01N33/53 ,  G01N33/582 ,  G01N2015/008 ,  G01N2015/1006 ,  G01N2015/149 ,  G01N2333/4704 ,  G01N2440/14

Abstract: Assays that can measure the effect of proteasome inhibitors on target cells in a biological sample are provided. The assays include evaluation of the effects of proteasome inhibitors on proteasome activity in cells in a biological sample.

公开(公告)号：US20180231525A1

公开(公告)日：2018-08-16

申请号：US15949155

申请日：2018-04-10

Applicant: Celica BIOMEDICAL

Inventor： Nina VARDJAN

IPC: G01N33/50 ,  A61K31/137 ,  A61K31/192 ,  A61K31/19 ,  A61K31/138 ,  A61K31/522 ,  G01N33/94 ,  A61K31/436 ,  G01N33/68

CPC classification number: G01N33/5058 ,  A61K31/137 ,  A61K31/138 ,  A61K31/19 ,  A61K31/192 ,  A61K31/436 ,  A61K31/522 ,  G01N33/5041 ,  G01N33/6896 ,  G01N33/94 ,  G01N2800/28

Abstract: The present invention pertains to a method for screening a compound useful in reducing astroglial edema, said method comprising: (i) providing a compound; (ii) bringing said compound in contact with an astrocyte; and (iii) determining the cAMP level in said astrocyte contacted with said compound; wherein said compound is identified as a compound useful in reducing astroglial edema, if the cAMP level in the astocyte increases after contact. The present invention further pertains to an agent elevating the cAMP level in astrocytes for use in reducing astroglial edema.

公开(公告)号：US20180194821A1

公开(公告)日：2018-07-12

申请号：US15900698

申请日：2018-02-20

Applicant: CHILDREN'S MEDICAL CENTER CORPORATION

Inventor： Anjana Rao ,  Stefan Feske ,  Patrick Hogan ,  Yousang Gwack

IPC: C07K14/47 ,  G01N33/50 ,  C07K16/18 ,  C12N15/90 ,  A61K35/12 ,  C12N5/16 ,  C07H21/04 ,  C12Q1/00 ,  C12N15/63

CPC classification number: C07K14/4702 ,  A61K35/12 ,  C07H21/04 ,  C07K16/18 ,  C12N5/16 ,  C12N15/63 ,  C12N15/907 ,  C12N2510/00 ,  C12Q1/00 ,  G01N33/5041

Abstract: Disclosed are methods of identifying an agent that modulates an NFAT regulator protein. One such method comprises contacting at least one test agent with a recombinant cell comprising at least one NFAT regulator protein or fragment or derivative thereof, assessing the effect of the test agent on an activity, interaction, expression, or binding to the NFAT regulator protein or fragment or derivative thereof, and identifying the test agent that has an effect on an activity, interaction, expression, or binding to the NFAT regulator protein or fragment or derivative thereof, whereby the identified test agent is characterized as an agent that modulates an NFAT regulator protein. Methods and tools for identifying an agent that modulates intracellular calcium, to screen for an agent that modulates NFAT regulator function, to diagnose unexplained immunodeficiency in a subject, and for identifying an agent for treating or preventing a disease or disorder associated with a NFAT regulator protein or calcium signaling are also disclosed.